Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Sell-side analysts expect that Viridian Therapeutics will post -4.03 earnings per share for ...

ByInvesting.com • Jun 11, 2024 Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye ...

What is the current share price of Viridian Therapeutics (VRDN)? Viridian Therapeutics's (VRDN) current share price is $20.08. This constitutes a price movement of 9.43% when compared to the share ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Morning Star 30 69 Jan 23, 2025 20:00 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Thomas Smith’s rating is based on the promising developments and strategic positioning of Viridian Therapeutics. The company has reported favorable Phase 3 results for its lead asset ...

VRDN Viridian Therapeutics Inc Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Veligrotug, ...

Undisputed super middleweight champion Canelo has turned up the heat on the potential duel, and Crawford has responded directly to the Mexican. This fight, which has been the subject of negotiations ...

WALTHAM, Mass., January 08, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...